Commercial Services and Supplies
Company Overview of Newcastle University
Newcastle University is an educational institution.
Newcastle, NE1 7RU
Founded in 1963
Key Executives for Newcastle University
Director of the Institute of Cell and Molecular Biosciences
Compensation as of Fiscal Year 2015.
Newcastle University Key Developments
Newcastle University Appoints Professor Julie Sanders as New Pro-Vice-Chancellor, Effective September 1, 2015
Aug 25 15
Newcastle University has appointed Professor Julie Sanders to the post of Pro-Vice-Chancellor, Faculty of Humanities and Social Sciences. Professor Sanders (pictured) will take up her new role from September 1, 2015 and joins Newcastle from the University of Nottingham Ningbo China where she was seconded as Vice Provost.
Newcastle University Appoints Amanda Broderick to Head its New London Campus
Jul 7 15
Newcastle University has appointed Professor Amanda Broderick to head its new London campus. Professor Broderick will take up her post as CEO and Director of Newcastle University London in September when the campus opens to students. An eminent social scientist, Professor Broderick also has an outstanding leadership track record. Professor Broderick joins Newcastle from the University of Salford where she is Pro-Vice-Chancellor (International) and Executive Dean of the College of Business & Law. Before moving to Salford, she was Principal of St. Cuthbert's Society - a Durham University College - and Deputy Dean of Durham Business School and has been a Professor of Marketing at multiple institutions in the UK and a Visiting Professor at universities internationally.
EpiStem Holdings Plc Announces the Signing of a Licensing Agreement with Cancer Research Technologies and Newcastle University
Apr 20 15
Epistem Holdings Plc announced the signing of a licensing agreement with Cancer Research Technologies (CRT) and Newcastle University for access to and development of patient derived Acute Lymphoblastic Leukemia (ALL) Primagraft samples for commercial use. This agreement builds upon Epistems expertise with cell line based disseminated models of leukemia, and will further enhance the Company's ability to support pre-clinical therapeutic evaluation in haematological disease. The licensed Primagraft models include a range of fully cytogenetically characterized samples, with complete clinical history. In addition to FACs based methodologies, several of these systemic Primagraft models have been stably lentivirally transduced with a luciferase vector allowing monitoring of in-life treatment responses and evaluation of disease severity using Epistems Bruker In Vivo Xtreme Optical imaging system.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries